Among the multitude of antiretroviral drugs (ARVs) licenced today there are few with dosing and safety information available for neonates, and the majority are liquid formulations. Current neonatal ARVs for postnatal prophylaxis (PNP) typically include ‘older’ drugs such as nevirapine and zidovudine, highlighting the need for more potent and safer ARVs in this population. WHO recommends solid ARV formulations for children, but only raltegravir granules are available for use in term neonates. However, this formulation requires multiple steps to administer, is not widely available, and has a low barrier to drug resistance. The time between the first introduction of new ARVs in adults and first data in neonates is often unacceptable. This delay is driven by the lack of pediatric friendly formulations, pharmacokinetic (PK) and safety data. Developmental changes and rapid growth from birth substantially impacts drug disposition, which are even more pronounced in preterm infants. It is difficult to extrapolate drug dosing from young children to neonates due to the immaturity of organs and metabolic enzyme activities in early life. Robust safety monitoring should also be performed as adverse events occur frequently, and reporting is complicated by toxicity grading tables not developed for preterm infants. An additional challenge to conducting PK studies in neonates is the limitation on blood draws owing to small total blood volume. Some of these limitations can be overcome by utilizing infant PK washout samples, sparse PK sampling techniques and application of PK modelling/simulation strategies to inform appropriate dosing. PK efficacy targets in adults are used in children, reducing the need to confirm efficacy in large numbers of neonates. Ongoing and future planned PK studies with solid ARV formulations may provide neonates with better access to effective and solid child-friendly formulations. New long-acting and effective ARVs on the horizon which can be administered intramuscularly or subcutaneously hold out promise for improving PNP options. Broadly neutralizing antibodies (bNAbs) have already been studied in neonates and have been shown to be safe. The combination of long-acting ARVs intravenously and/or subcutaneously administered bNAbs may offer protection against HIV transmission. As a pediatric community we should advocate for access to these newer ARVs to ensure that neonates are not left behind.